These findings suggest that age was an independent risk factor associated with late distant recurrence in young patients with ER-positive, ERBB2-negative breast cancer, indicating the need for tailored management and follow-up strategies, particularly for younger patients. This evidence concerns the gene ESR1 and breast carcinoma.